QNRX NASDAQ
Quoin Pharmaceuticals, Ltd.
1W: -30.5%
1M: -33.7%
3M: -2.8%
YTD: -68.2%
1Y: -38.2%
3Y: -97.0%
5Y: -100.0%
$4.47
-0.25 (-5.30%)
Weekly Expected Move ±11.0%
$3
$4
$4
$5
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$101K
+0.0% ▲
Operating Income
-$16M
-72.3% ▼
Net Income
-$15.8B
-176242.6% ▼
EPS (Diluted)
$-14796.26
-22033.5% ▼
EBITDA
-$16M
-73.1% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $101K |
| Gross Profit | $0 | $0 | $0 | $0 | -$101K |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $2M | $3M | $3M | $4M | $9.8B |
| SG&A Expenses | $4M | $7M | $6M | $6M | $6.5B |
| Operating Expenses | $6M | $9M | $9M | $10M | $16M |
| Operating Income | -$6M | -$9M | -$9M | -$10M | -$16M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $1M | $714K | $0 | $0 | $0 |
| Income Before Tax | -$21M | -$9M | -$9M | -$9M | -$16M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$21M | -$9M | -$9M | -$9M | -$15.8B |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-28543.20 | $-22.97 | $-337.47 | $-66.85 | $-14796.26 |
| EBITDA | -$20M | -$9M | -$9M | -$9M | -$16M |
| Shares Outstanding | 1597 | 403883 | 25741 | 133964 | 1M |